Navigation Links
Xytis Names Gordon H. Busenbark as Chief Financial Officer
Date:10/19/2007

IRVINE, Calif., Oct. 19 /PRNewswire/ -- Xytis Inc., a privately held biotechnology company focused on developing novel therapeutics to treat central nervous system (CNS) diseases, today announced that Gordon H. Busenbark has joined the company as Chief Financial Officer. Mr. Busenbark has more than 25 years of experience in the pharmaceutical, biotechnology and medical devices industries. During a 23 year career at Baxter Healthcare, Mr. Busenbark held a number of senior-level financial, operational and general management positions in both the U.S. and Europe. This included roles as Chief Financial Officer of Immuno AG when the company was acquired by Baxter, and President of Baxter's global Plasma Therapeutics business. Mr. Busenbark's most recent role was as Chief Financial Officer at Encysive Pharmaceuticals, where his accomplishments included raising more than $100 million in debt and equity financing.

"We are very pleased to have Gordon join Xytis," said Vincent F. Simmon, CEO and President. "He brings great financial and operational experience, both from a large pharmaceutical company perspective as well as from that of a smaller biotechnology company. Gordon joins us at an exciting time for Xytis. Our Phase 2 clinical trial in Traumatic Brain Injury (TBI) is approximately half way enrolled. Also, there is considerable partnering interest in two of our pre-clinical programs; positive allosteric modulators of GABA-A receptor and of alpha-7 nicotinic acetylcholine receptors. His experience and assistance in financing and marshalling these programs forward will be greatly welcomed."

Mr. Busenbark has both a B.S. in Accounting and an MBA from the University of Utah.

About Xytis

Xytis Inc. is a privately held discovery and development biopharmaceutical company, headquartered in Irvine, California, and having a clinical development group in Nyon, Switzerland, focused on innovative CNS drug candidates. The Company's investors include Atlas Venture, Sanderling Ventures, CDC Innovation, and Ventech. Xytis has a rich portfolio of proprietary preclinical compounds that are novel, highly selective allosteric modulators of nicotinic acetylcholine receptors (nAChRs), GABA-A receptors and other well-validated CNS targets. The Company has two compounds in clinical development -- Neboglamine (XY2401) and Anatibant (XY2405). Neboglamine is a selective norepinephrine uptake inhibitor, which has completed single and multiple dose Phase 1 studies, and is intended for the treatment of patients with schizophrenia and/or major depression. XY2401 has been well tolerated in the Phase 1 studies. Anatibant (XY2405), Xytis' lead compound, is under development for TBI with a Phase 2 multi-center trial ongoing in nine countries worldwide with more than 200 patients enrolled. See http://www.xytis.com for additional information.


'/>"/>
SOURCE Xytis Inc.
Copyright©2007 PR Newswire.
All rights reserved

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... "The World Market for Companion Diagnostic Tests" report to ... World Market for Companion Diagnostics The World ... diagnostic and personalized medicine diagnostics. Market analysis in the report ... Diagnostics Test Market (In Vitro Diagnostic Kits) by Region (N. ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
Breaking Medicine Technology:
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
Breaking Medicine News(10 mins):